News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,322 Results
Type
Article (42023)
Company Profile (252)
Press Release (673047)
Multimedia
Podcasts (55)
Webinars (12)
Section
Business (208494)
Career Advice (2104)
Deals (35909)
Drug Delivery (100)
Drug Development (82182)
Employer Resources (176)
FDA (16378)
Job Trends (15093)
News (351653)
Policy (33135)
Tag
Academia (2644)
Accelerated approval (5)
Adcomms (26)
Allergies (86)
Alliances (50414)
ALS (97)
Alzheimer's disease (1407)
Antibody-drug conjugate (ADC) (137)
Approvals (16373)
Artificial intelligence (270)
Autoimmune disease (23)
Automation (17)
Bankruptcy (363)
Best Places to Work (11778)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (177)
Bladder cancer (81)
Brain cancer (29)
Breast cancer (302)
Cancer (2383)
Cardiovascular disease (182)
Career advice (1762)
Career pathing (32)
CAR-T (164)
Cell therapy (458)
Cervical cancer (20)
Clinical research (66988)
Collaboration (881)
Company closure (2)
Compensation (576)
Complete response letters (19)
COVID-19 (2625)
CRISPR (44)
C-suite (265)
Cystic fibrosis (102)
Data (2407)
Decentralized trials (2)
Denatured (22)
Depression (45)
Diabetes (286)
Diagnostics (6518)
Digital health (20)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (125)
Drug pricing (110)
Drug shortages (25)
Duchenne muscular dystrophy (102)
Earnings (89092)
Editorial (39)
Employer branding (21)
Employer resources (149)
Events (115476)
Executive appointments (764)
FDA (17791)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (794)
Gene editing (113)
Generative AI (21)
Gene therapy (334)
GLP-1 (734)
Government (4524)
Grass and pollen (4)
Guidances (174)
Healthcare (19134)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (127)
Indications (30)
Infectious disease (2773)
Inflammatory bowel disease (146)
Inflation Reduction Act (9)
Influenza (53)
Intellectual property (99)
Interviews (325)
IPO (16730)
IRA (40)
Job creations (3725)
Job search strategy (1498)
Kidney cancer (10)
Labor market (43)
Layoffs (485)
Leadership (20)
Legal (8045)
Liver cancer (77)
Lung cancer (338)
Lymphoma (164)
Machine learning (9)
Management (60)
Manufacturing (337)
MASH (79)
Medical device (13636)
Medtech (13641)
Mergers & acquisitions (19772)
Metabolic disorders (731)
Multiple sclerosis (85)
NASH (16)
Neurodegenerative disease (101)
Neuropsychiatric disorders (28)
Neuroscience (1988)
NextGen: Class of 2025 (6622)
Non-profit (4590)
Now hiring (41)
Obesity (384)
Opinion (215)
Ovarian cancer (82)
Pain (92)
Pancreatic cancer (90)
Parkinson's disease (160)
Partnered (22)
Patents (251)
Patient recruitment (121)
Peanut (46)
People (58667)
Pharmaceutical (66)
Pharmacy benefit managers (20)
Phase I (20865)
Phase II (29489)
Phase III (21954)
Pipeline (1472)
Policy (148)
Postmarket research (2649)
Preclinical (8935)
Press Release (64)
Prostate cancer (108)
Psychedelics (32)
Radiopharmaceuticals (248)
Rare diseases (398)
Real estate (6055)
Recruiting (66)
Regulatory (22735)
Reports (50)
Research institute (2387)
Resumes & cover letters (358)
Rett syndrome (7)
RNA editing (7)
RSV (42)
Schizophrenia (74)
Series A (136)
Series B (92)
Service/supplier (11)
Sickle cell disease (55)
Special edition (16)
Spinal muscular atrophy (148)
Sponsored (30)
Startups (3637)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (53)
The Weekly (31)
Vaccines (711)
Venture capitalists (42)
Weight loss (244)
Women's health (38)
Worklife (17)
Date
Today (123)
Last 7 days (901)
Last 30 days (3522)
Last 365 days (32692)
2025 (12674)
2024 (35532)
2023 (40487)
2022 (51675)
2021 (56301)
2020 (54766)
2019 (47457)
2018 (35740)
2017 (32833)
2016 (32300)
2015 (38442)
2014 (32127)
2013 (27105)
2012 (29398)
2011 (30031)
2010 (28126)
Location
Africa (764)
Alabama (55)
Alaska (7)
Arizona (238)
Arkansas (13)
Asia (39423)
Australia (6504)
California (6625)
Canada (2112)
China (553)
Colorado (281)
Connecticut (288)
Delaware (162)
Europe (85955)
Florida (980)
Georgia (220)
Idaho (57)
Illinois (564)
India (26)
Indiana (326)
Iowa (11)
Japan (178)
Kansas (108)
Kentucky (24)
Louisiana (12)
Maine (72)
Maryland (946)
Massachusetts (4915)
Michigan (235)
Minnesota (413)
Mississippi (2)
Missouri (87)
Montana (27)
Nebraska (25)
Nevada (70)
New Hampshire (64)
New Jersey (1838)
New Mexico (28)
New York (1856)
North Carolina (1044)
North Dakota (8)
Northern California (2914)
Ohio (217)
Oklahoma (14)
Oregon (34)
Pennsylvania (1456)
Puerto Rico (13)
Rhode Island (33)
South America (1145)
South Carolina (27)
South Dakota (1)
Southern California (2484)
Tennessee (108)
Texas (980)
United States (24760)
Utah (194)
Virginia (157)
Washington D.C. (67)
Washington State (579)
West Virginia (3)
Wisconsin (63)
715,322 Results for "dyadic international inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the diagnostic, nutrition and cell culture markets.
June 28, 2024
·
4 min read
Press Releases
Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress
May 15, 2025
·
17 min read
Press Releases
Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
May 2, 2025
·
3 min read
Press Releases
Dyadic to Attend Multiple Industry Events in March 2025
March 7, 2025
·
3 min read
Press Releases
Dyadic Reports 2024 Year-End Financial Results and Business Updates
March 27, 2025
·
17 min read
Business
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced its financial results for the first quarter of 2024 and highlighted recent Company progress.
May 14, 2024
·
21 min read
Dyadic to Present at BioProcess International
Dyadic International, Inc. today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.
September 12, 2023
·
3 min read
Business
Dyadic to Attend Industry Events in April 2024
Dyadic International, Inc. announced that its management will be attending the following industry events during the month of April 2024.
March 27, 2024
·
3 min read
Business
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced that it will report its financial results for the first quarter 2024 and host a corporate update conference call on Tuesday, May 14, 2024.
April 30, 2024
·
3 min read
Press Releases
Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference
January 7, 2025
·
6 min read
1 of 71,533
Next
